Concepedia

P.A. Jänne

PJ

Statistics

Publications

3

Citations

97

H-Index

3

Active since

2015

Affiliations

Dana-Farber Cancer Institute(Current)

P.A. Jänne is an author at Dana-Farber Cancer Institute specializing in malignant neoplasms, phase ii investigation, and pharmacology.

Publications per year

2015–2024

3

Publications

3

16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)

Benjamin Besse, Melissa Johnson, P.A. Jänne et al. · European Journal of Cancer · 2015 · 72 citations

Medicine, Oncology, Pharmacology +16

FP01.05 The ASCENT Trial: A Phase II Study of Neoadjuvant/Adjuvant Afatinib, Chemoradiation +/- Surgery for Stage III EGFR-Mutant NSCLC

Andrew J. Piper‐Vallillo, Raymond H. Mak, Michael Lanuti et al. · Journal of Thoracic Oncology · 2021 · 13 citations · Full text

Medicine, Oncology, Pharmacology +17

PL04.03 Safety and Efficacy of BAY 2927088 In Patients with HER2-Mutant NSCLC: Expansion Cohort from the Phase I/II SOHO-01 Study

Xiuning Le, Nicolas Girard, P.A. Jänne et al. · Journal of Thoracic Oncology · 2024 · 12 citations · Full text

Medicine, Oncology, Pharmacology +10

1–3 of 3